{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:56:37Z","timestamp":1768834597629,"version":"3.49.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.mcna.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:28:57Z","timestamp":1744493337000},"page":"857-873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk Factors and Management of Cancer-Associated Thrombosis"],"prefix":"10.1016","volume":"109","author":[{"given":"Kristina","family":"Vrotniakaite-Bajerciene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.mcna.2025.01.004_bib1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mcna.2025.01.004_bib2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.004_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","article-title":"Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006","volume":"103","author":"Cronin-Fenton","year":"2010","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib4","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11523-022-00905-x","article-title":"Thromboembolism in patients with metastatic urothelial cancer treated with immune checkpoint inhibitors","volume":"17","author":"Sheng","year":"2022","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jth.14630","article-title":"Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors","volume":"18","author":"Gervaso","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.004_bib7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.mcna.2025.01.004_bib8","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.mcna.2025.01.004_bib9","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.004_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2025.01.004_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2023.12.016","article-title":"Cancer-associated venous thromboembolism in the direct oral anticoagulants era: insight from the COMMAND VTE Registry-2","volume":"234","author":"Chatani","year":"2024","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jval.2017.09.015","article-title":"What impact does venous thromboembolism and bleeding have on cancer patients\u2019 quality of life?","volume":"21","author":"Lloyd","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.mcna.2025.01.004_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"3","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0042-1758835","article-title":"Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment","volume":"123","author":"McBane","year":"2023","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.mcna.2025.01.004_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2021.100075","article-title":"Risk assessment models of cancer-associated thrombosis - potentials and perspectives","volume":"5","author":"Moik","year":"2021","journal-title":"Thrombosis Update"},{"issue":"10","key":"10.1016\/j.mcna.2025.01.004_bib17","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib19","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2025.01.004_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","article-title":"Mechanisms and biomarkers of cancer-associated thrombosis","volume":"225","author":"Kim","year":"2020","journal-title":"Transl Res"},{"issue":"25","key":"10.1016\/j.mcna.2025.01.004_bib21","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","article-title":"D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study","volume":"27","author":"Ay","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.004_bib22","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00277-010-1111-1","article-title":"Circulating procoagulant microparticles in cancer patients","volume":"90","author":"Thaler","year":"2011","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.004_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.13951","article-title":"Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients","volume":"16","author":"Mauracher","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.mcna.2025.01.004_bib25","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1055\/s-0038-1673401","article-title":"Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer","volume":"118","author":"Grilz","year":"2018","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cei.12308","article-title":"Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients","volume":"177","author":"Reitter","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.mcna.2025.01.004_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11122020","article-title":"Low systemic levels of chemokine C-C motif ligand 3 (CCL3) are associated with a high risk of venous thromboembolism in patients with glioma","volume":"11","author":"Mir Seyed Nazari","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/1078-0432.CCR-14-3358","article-title":"Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the Vienna cancer and thrombosis study (CATS)","volume":"22","author":"Posch","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2025.01.004_bib30","first-page":"998","article-title":"Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis","volume":"5","author":"den","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib31","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00520-013-1792-9","article-title":"Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score","volume":"21","author":"Ahn","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.mcna.2025.01.004_bib32","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ejim.2016.08.001","article-title":"External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis","volume":"36","author":"Astruc","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib33","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3324\/haematol.2019.222828","article-title":"Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"105","author":"Delluc","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib34","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.14783","article-title":"Prognosis in patients with cancer-associated venous thromboembolism: comparison of the RIETE-VTE and modified Ottawa score","volume":"18","author":"Pfaundler","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"13","key":"10.1016\/j.mcna.2025.01.004_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133729","article-title":"The Ottawa Score performs poorly to identify cancer patients at high risk of recurrent venous thromboembolism: insights from the TROPIQUE study and updated meta-analysis","volume":"11","author":"Frere","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1486-7497","article-title":"Failure of the Ottawa score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study","volume":"122","author":"Girard","year":"2022","journal-title":"Thromb Haemost"},{"issue":"25","key":"10.1016\/j.mcna.2025.01.004_bib37","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"Chee","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.004_bib38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1160\/TH08-02-0125","article-title":"Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Trujillo-Santos","year":"2008","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.004_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MBC.0b013e328341f030","article-title":"Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies","volume":"22","author":"Louzada","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib40","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jtha.2023.04.010","article-title":"Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study","volume":"21","author":"Lap\u00e9bie","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mcna.2025.01.004_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.mcna.2025.01.004_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2018.01.009","article-title":"Predicting the risk of recurrent venous thromboembolism in patients with cancer: a prospective cohort study","volume":"163","author":"van Es","year":"2018","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib43","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41416-018-0269-5","article-title":"D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis","volume":"119","author":"Jara-Palomares","year":"2018","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.mcna.2025.01.004_bib44","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2016.67.4564","article-title":"Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial","volume":"35","author":"Khorana","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.mcna.2025.01.004_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112771","article-title":"Biomarkers of venous thromboembolism recurrence after discontinuation of low molecular weight heparin treatment for cancer-associated thrombosis (HISPALIS-Study)","volume":"14","author":"Otero","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.004_bib46","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib47","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"de Winter","year":"2022","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.mcna.2025.01.004_bib48","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism - from the COMMAND VTE registry","volume":"84","author":"Nishimoto","year":"2020","journal-title":"Circ J"},{"issue":"Supplement 1","key":"10.1016\/j.mcna.2025.01.004_bib49","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1182\/blood-2023-191029","article-title":"Risk factors associated with anticoagulant-related bleeding in patients with cancer-associated thrombosis","volume":"142","author":"Loncharich","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib50","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2174\/0929867324666170718124742","article-title":"Biomarkers associated with bleeding risk in the setting of atrial fibrillation","volume":"26","author":"Sideris","year":"2019","journal-title":"Curr Med Chem"},{"issue":"18","key":"10.1016\/j.mcna.2025.01.004_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12186050","article-title":"Thrombin generation is associated with venous thromboembolism recurrence, but not with major bleeding and death in the elderly: a prospective multicenter cohort study","volume":"12","author":"Vrotniakaite-Bajerciene","year":"2023","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.004_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072018","article-title":"Delayed thrombin generation is associated with minor bleedings in venous thromboembolism patients on rivaroxaban: usefulness of calibrated automated thrombography","volume":"9","author":"Zalewski","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jth.15559","article-title":"Growth differentiation factor-15 for prediction of bleeding in cancer patients","volume":"20","author":"Mulder","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"issue":"15","key":"10.1016\/j.mcna.2025.01.004_bib55","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.mcna.2025.01.004_bib56","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.004_bib57","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.004_bib58","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.004_bib59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.004_bib60","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"issue":"22","key":"10.1016\/j.mcna.2025.01.004_bib61","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.004_bib62","article-title":"Comparative efficacy of direct oral anticoagulants and low-molecular-weight heparin in cancer-associated thromboembolism: a systematic review and meta-analysis","volume":"15","author":"Patel","year":"2023","journal-title":"Cureus"},{"issue":"16","key":"10.1016\/j.mcna.2025.01.004_bib63","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib64","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib65","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1055\/s-0040-1712913","article-title":"Venous thromboembolic diseases: diagnosis, management and thrombophilia testing: observations on NICE guideline [NG158]","volume":"120","author":"Schulman","year":"2020","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.004_bib66","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.004_bib67","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib68","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.004_bib70","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1055\/s-0043-1770783","article-title":"Rivaroxaban versus apixaban for treatment of cancer-associated venous thromboembolism in patients at lower risk of bleeding","volume":"7","author":"Caroti","year":"2023","journal-title":"TH Open"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2025.01.004_bib71","article-title":"Drug-drug interactions: implications for anticoagulation, with focus in patients with cancer","volume":"213","author":"Wang","year":"2022","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/j.mcna.2025.01.004_bib72","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/jth.15519","article-title":"Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004012","article-title":"Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: a population-based cohort study","volume":"19","author":"Khan","year":"2022","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.004_bib74","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/bjc.1992.67","article-title":"The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding","volume":"65","author":"Francis","year":"1992","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1016\/j.mcna.2025.01.004_bib75","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-14-2887-T","article-title":"Warfarin blocks gas6-mediated axl activation required for pancreatic cancer epithelial plasticity and metastasis","volume":"75","author":"Kirane","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.mcna.2025.01.004_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"van Hylckama Vlieg","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.004_bib77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jth.15599","article-title":"Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: a systematic review","volume":"20","author":"Moik","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib78","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.mcna.2025.01.004_bib79","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib80","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up","volume":"20","author":"Larsen","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.004_bib81","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib82","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study","volume":"122","author":"Mah\u00e9","year":"2022","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.004_bib83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/a-2173-7729","article-title":"Recurrent venous thromboembolism in patients on anticoagulation: an update based on the revised AWMF S2k guideline","volume":"44","author":"Klamroth","year":"2024","journal-title":"H\u00e4mostaseologie"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib85","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.004_bib86","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.004_bib87","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.004_bib88","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","article-title":"Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.004_bib92","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Moik","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12959-022-00399-7","article-title":"Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis","volume":"20","author":"Rungjirajittranon","year":"2022","journal-title":"Thromb J"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib94","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib95","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib96","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the caravaggio study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.mcna.2025.01.004_bib97","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.mayocp.2021.04.026","article-title":"Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism","volume":"96","author":"Houghton","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"16","key":"10.1016\/j.mcna.2025.01.004_bib98","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"Giustozzi","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.004_bib99","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtha.2023.10.011","article-title":"Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review","volume":"22","author":"Iyengar","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.004_bib100","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.mcna.2025.01.004_bib101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2023.05.012","article-title":"Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis","volume":"227","author":"Wang","year":"2023","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.004_bib102","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"24","key":"10.1016\/j.mcna.2025.01.004_bib103","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","article-title":"Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study","volume":"5","author":"Carney","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.004_bib104","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.15748","article-title":"Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: the CAVEaT multicenter prospective cohort","volume":"20","author":"Booth","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.004_bib106","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.19414","article-title":"Cancer-associated venous thrombosis in adults (second edition): a British Society for Haematology Guideline","volume":"205","author":"Alikhan","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:11:11Z","timestamp":1749503471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712525000148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0025712525000148"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2025.01.004","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors and Management of Cancer-Associated Thrombosis","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}